Fate Therapeutics (FATE)

Fate Therapeutics (FATE) Stock Price & Analysis


FATE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.99 - $23.96
Previous Close$2.18
Average Volume (3M)2.28M
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)$377.94M
Total Debt (Recent Filing)$106.35M
Price to Earnings (P/E)-1.0
Nov 02, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding98,562,432
10 Day Avg. Volume4,300,911
30 Day Avg. Volume2,283,333
Standard Deviation0.19
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)221.84
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Price Target Upside211.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $1.99 and its highest was $23.96 in the past 12 months.
    What is Fate Therapeutics’s market cap?
    Currently, no data Available
    When is Fate Therapeutics’s upcoming earnings report date?
    Fate Therapeutics’s upcoming earnings report date is Nov 02, 2023 which is in 34 days.
      How were Fate Therapeutics’s earnings last quarter?
      Fate Therapeutics released its earnings results on Aug 08, 2023. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.589 by $0.049.
        Is Fate Therapeutics overvalued?
        According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Fate Therapeutics pay dividends?
          Fate Therapeutics does not currently pay dividends.
          What is Fate Therapeutics’s EPS estimate?
          Fate Therapeutics’s EPS estimate is -$0.56.
            How many shares outstanding does Fate Therapeutics have?
            Fate Therapeutics has 98,562,430 shares outstanding.
              What happened to Fate Therapeutics’s price movement after its last earnings report?
              Fate Therapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.589. Following the earnings report the stock price went down -3.683%.
                Which hedge fund is a major shareholder of Fate Therapeutics?
                Among the largest hedge funds holding Fate Therapeutics’s share is Baker Bros Advisors LP. It holds Fate Therapeutics’s shares valued at 8M.


                  Fate Therapeutics Stock Smart Score

                  The Fate Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Fate Therapeutics

                  Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.


                  Top 5 ETFs holding FATE

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Fidelity Nasdaq Composite Index ETF
                  iShares Russell 3000 ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold FATE. The ETFs are listed according to market value of FATE within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Frequency Therapeutics
                  Voyager Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis